Lv4
435 积分 2020-08-03 加入
ADC target profiling in NSCLC: Generalizable AI separates TROP-2 and cMET phenotypes
9天前
已完结
Microbiota biomarkers as predictors on immunotherapy response in patients with advanced non-small cell lung cancer
15天前
已关闭
Antibody–drug conjugates in lung cancer: current landscape and future perspectives
15天前
已完结
Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score
21天前
已完结
What practicing pathologists and oncologists should know about the new computational pathology-based companion diagnostic tools
21天前
已完结
Trastuzumab deruxtecan: Redefining precision oncology across HER2-driven cancers
25天前
已完结
Advancing Frontline Therapy in Metastatic NSCLC: Lessons From EVOKE-02 on Antibody–Drug Conjugates–Immunotherapy Combination
26天前
已关闭
Advancing Frontline Therapy in Metastatic NSCLC: Lessons From EVOKE-02 on Antibody–Drug Conjugates–Immunotherapy Combination
26天前
已关闭
The Cell and Gene Therapy Access Model — A Vision for Future Development
26天前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
27天前
已完结
皖公网安备34019202002308
